Dr. Anna Kazanchyan has over 20 years of experience as an executive in both the biotech and investment industries. Dr. Kazanchyan is currently CEO and Chairperson of Saghmos Therapeutics, a company focused on the prevention of contrast-induced acute kidney injury. She is also the founder and Managing Partner of Primary i-Research, where she provides due diligence to leading healthcare investment funds and evaluates investment prospects of biopharmaceutical companies based on the scientific, clinical, regulatory, and commercial outlook for their products. Previously, Dr. Kazanchyan served as Senior Vice President of Product Development at Ovid Therapeutics from (2015-2016). She also served as Senior Vice President of Business Development at Ovid Therapeutics from (2014-2015). Prior to her positions in the biotech industry, Dr. Kazanchyan was Senior Biotechnology Analyst at Wachovia Securities, and was a member of the Biotechnology Equity Research teams at Goldman Sachs and Citigroup, respectively. She received her medical degree from Harvard Medical School, and she graduated summa cum laude with a B.A. degree in Biology from Clark University.